George D. Yancopoulos (born 1959) is a Greek-American biomedical scientist who is the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals.[1]
Yancopoulos is the holder of more than 100 patents.[2] He is a principal inventor and developer of Regeneron's ten FDA-approved or -authorized treatments, as well as of Regeneron's foundational technologies for target and drug development, such as its proprietary TRAP technology, and the VelociGene and VelocImmune antibody technologies.[3][4]
No comments:
Post a Comment